CN101506217B - 埃坡霉素b的晶型及在药物组合物中的用途 - Google Patents

埃坡霉素b的晶型及在药物组合物中的用途 Download PDF

Info

Publication number
CN101506217B
CN101506217B CN2007800304132A CN200780030413A CN101506217B CN 101506217 B CN101506217 B CN 101506217B CN 2007800304132 A CN2007800304132 A CN 2007800304132A CN 200780030413 A CN200780030413 A CN 200780030413A CN 101506217 B CN101506217 B CN 101506217B
Authority
CN
China
Prior art keywords
epothilone
activeconstituents
transfusion
crystal
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800304132A
Other languages
English (en)
Chinese (zh)
Other versions
CN101506217A (zh
Inventor
E·屈斯特斯
M·马兹
F·施托瓦塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101506217(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101506217A publication Critical patent/CN101506217A/zh
Application granted granted Critical
Publication of CN101506217B publication Critical patent/CN101506217B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800304132A 2006-08-16 2007-08-14 埃坡霉素b的晶型及在药物组合物中的用途 Expired - Fee Related CN101506217B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06119043 2006-08-16
EP06119043.5 2006-08-16
PCT/EP2007/007173 WO2008019820A2 (en) 2006-08-16 2007-08-14 Crystal form of epothilone b and use in pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CN101506217A CN101506217A (zh) 2009-08-12
CN101506217B true CN101506217B (zh) 2012-09-05

Family

ID=37685905

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800304132A Expired - Fee Related CN101506217B (zh) 2006-08-16 2007-08-14 埃坡霉素b的晶型及在药物组合物中的用途

Country Status (22)

Country Link
US (1) US8178566B2 (https=)
EP (1) EP2064216A2 (https=)
JP (1) JP2010500387A (https=)
KR (1) KR20090038902A (https=)
CN (1) CN101506217B (https=)
AR (1) AR062375A1 (https=)
AU (1) AU2007286454A1 (https=)
BR (1) BRPI0715963A2 (https=)
CA (1) CA2658475A1 (https=)
CL (1) CL2007002362A1 (https=)
IL (1) IL196558A0 (https=)
MA (1) MA30656B1 (https=)
MX (1) MX2009001635A (https=)
MY (1) MY148355A (https=)
NO (1) NO20091081L (https=)
NZ (1) NZ574194A (https=)
PE (1) PE20081317A1 (https=)
RU (1) RU2009109352A (https=)
TN (1) TN2009000044A1 (https=)
TW (1) TW200815455A (https=)
WO (1) WO2008019820A2 (https=)
ZA (1) ZA200900227B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1468243A (zh) * 2000-08-16 2004-01-14 ����˹�ж�-����˹˹������˾ epothilone类似物的多晶型物
CN1535971A (zh) * 1998-02-19 2004-10-13 ��˹��ŵ�� 细胞抑制剂及其晶形的发酵制备方法
CN1705662A (zh) * 2002-09-23 2005-12-07 布里斯托尔-迈尔斯斯奎布公司 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x－射线晶体结构

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287775B6 (sk) 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535971A (zh) * 1998-02-19 2004-10-13 ��˹��ŵ�� 细胞抑制剂及其晶形的发酵制备方法
CN1468243A (zh) * 2000-08-16 2004-01-14 ����˹�ж�-����˹˹������˾ epothilone类似物的多晶型物
CN1705662A (zh) * 2002-09-23 2005-12-07 布里斯托尔-迈尔斯斯奎布公司 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x－射线晶体结构

Also Published As

Publication number Publication date
KR20090038902A (ko) 2009-04-21
PE20081317A1 (es) 2008-10-28
NO20091081L (no) 2009-03-16
MA30656B1 (fr) 2009-08-03
TN2009000044A1 (en) 2010-08-19
IL196558A0 (en) 2009-11-18
AU2007286454A1 (en) 2008-02-21
CA2658475A1 (en) 2008-02-21
MY148355A (en) 2013-03-29
US8178566B2 (en) 2012-05-15
AR062375A1 (es) 2008-11-05
ZA200900227B (en) 2009-12-30
CL2007002362A1 (es) 2008-08-08
BRPI0715963A2 (pt) 2013-08-06
MX2009001635A (es) 2009-02-23
WO2008019820A2 (en) 2008-02-21
RU2009109352A (ru) 2010-09-27
TW200815455A (en) 2008-04-01
WO2008019820A3 (en) 2008-04-17
US20100160393A1 (en) 2010-06-24
NZ574194A (en) 2011-12-22
CN101506217A (zh) 2009-08-12
EP2064216A2 (en) 2009-06-03
JP2010500387A (ja) 2010-01-07

Similar Documents

Publication Publication Date Title
ES2324378T3 (es) Composicion farmaceutica que contiene epotilona.
CN1084332C (zh) 含蝶呤衍生物的活性氧消除剂
US6683100B2 (en) Organic compounds
CN101506217B (zh) 埃坡霉素b的晶型及在药物组合物中的用途
JPH10507177A (ja) Ｇｆ１２０９１８ａを含む非経口医薬組成物
MXPA06002393A (es) Tratamiento de cancer con epotilomas.
CN111481640B (zh) 抗肝癌微乳纳米组合物及其应用
JP2011529930A (ja) 注射可能タキサン医薬品組成物
AU2007262496A1 (en) Pharmaceutical composition for injectional, particularly targeted local administration
EP1363892B1 (en) Method for the production of a stable pharmaceutical form of paclitaxel
EP2034957B1 (en) Pharmaceutical composition for oral administration
EP1986630A2 (en) A taxane derivative containing pharmaceutical composition with improved therapeutic efficacy
KR20090106666A (ko) 유기화합물 함유 조성물
HK1033809B (en) Pharmaceutical formulation containing epothilone
HK1060733B (en) Method for the production of a stable pharmaceutical form of paclitaxel

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905

Termination date: 20130814